Next Article in Journal
Comparison of Behavioral Changes and Brain Activity between Adolescents with Internet Gaming Disorder and Student Pro-Gamers
Next Article in Special Issue
Surgical Smoke—Hazard Perceptions and Protective Measures in German Operating Rooms
Previous Article in Journal
The Prevalence and Socio-Demographic Correlates of Depressive Symptoms in Early Adolescents in China: Differences in Only Child and Non-Only Child Groups
Previous Article in Special Issue
Culture of Blame—An Ongoing Burden for Doctors and Patient Safety
Open AccessArticle

Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany

1
Competence Centre for Epidemiology and Health Services Research for Healthcare Professionals (CVcare), University Medical Centre Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany
2
Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Centre Hamburg-Eppendorf (UKE), 20246 Hamburg, Germany
3
Chair of Healthcare Management and Health Services Research, University of Bayreuth, 95445 Bayreuth, Germany
4
Department of Occupational Medicine, Hazardous Substances and Public Health, Institution for Statutory Accident Insurance and Prevention in the Health and Welfare Services (BGW), 22089 Hamburg, Germany
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2020, 17(2), 440; https://doi.org/10.3390/ijerph17020440
Received: 7 November 2019 / Revised: 3 January 2020 / Accepted: 6 January 2020 / Published: 9 January 2020
Around 1% of the world’s population is infected with hepatitis C. The introduction of new direct-acting antiviral agents (DAAs) in 2014 has substantially improved hepatitis C treatment outcomes. Our objective was to evaluate the long-term cost effectiveness of DAAs in health care personnel (HP) with confirmed occupational diseases in Germany. A standardised database from a German statutory accident insurance was used to analyse the cost-effectiveness ratio for the DAA regimen in comparison with interferon-based triple therapies. Taking account of the clinical progression of the disease, a Markov model was applied to perform a base case analysis for a period of 20 years. The robustness of the results was determined using a univariate deterministic sensitivity analysis. The results show that treatment with DAAs is more expensive, but also more effective than triple therapies. The model also revealed that the loss of 3.23 life years can be averted per patient over the 20 years. Compared to triple therapies, DAA treatment leads to a higher sustained virologic response (SVR). Although this results in a decrease of costs in the long term, e.g., pension payments, DAA therapy will cause greater expense in the future due to the high costs of the drugs. View Full-Text
Keywords: hepatitis C; cost-effectiveness analysis; interferon-free therapies; direct-acting antiviral agents; occupational disease hepatitis C; cost-effectiveness analysis; interferon-free therapies; direct-acting antiviral agents; occupational disease
Show Figures

Figure 1

MDPI and ACS Style

Runge, M.; Krensel, M.; Westermann, C.; Bindl, D.; Nagels, K.; Augustin, M.; Nienhaus, A. Cost-Effectiveness Analysis of Direct-Acting Antiviral Agents for Occupational Hepatitis C Infections in Germany. Int. J. Environ. Res. Public Health 2020, 17, 440.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop